Solvay sells facilities to contract manufacturer

By staff reporter

- Last updated on GMT

Related tags Pharmacology Solvay

Solvay Pharmaceuticals has sold two of its manufacturing facilities
that it no longer considers as core. The new owners will now act as
a contract manufacturer for Solvay, the company announced today.

The Belgian firm made the "strategic move"​ by selling its Baudette, north Minnesota facilities to ANI Pharmaceuticals, a US pharmaceutical company focused on generic prescription and over the counter product markets as well as contract manufacturing. The Main Street and hormone facilities include the manufacture and packaging of Estratest, a drug which alleviates the vasomotor symptoms of menopause, and the packaging of Prometrium, which is used in the prevention of endometrial hyperplasia in post-menopausal women, as well as Creon minimicrospheres, used for the treatment of pancreatic enzyme deficiency in cystic fibrosis. ANI will take over all the current drug manufacturing and packaging activities performed at the Baudette facilities on behalf of Solvay under a new contract manufacturing deal it has inked with the firm, which also includes the provision of contract laboratory services. The move, effective April 30, is part of Solvay's ongoing "global manufacturing strategic planning which involves maximising the company's resources and where they should best be invested,"​ company spokesperson Neil Hirsch told This is the first time a relationship has been forged between the two companies, said Hirsch, who also said that while the terms of the contract could not be disclosed, there were no job losses as a result of the sale.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more